Increasing Number Of Launches In Generic Version Of Budesonide Inhaler Drive The Growth Of The Inhaler Market

Budesonide is an artificial glucocorticoid steroid related to the naturally-occurring hormone, cortisol or hydrocortisone, which is produced in the adrenal glands. It is used for treating asthma. Budesonide is sold under the brand name Pulmicort. Each budesonide inhaler is designed to provide 60 to 120 inhalations depending on the device. Increasing air population is expected to lead to high prevalence of asthma worldwide. According to World Health Organization (WHO), asthma is not just a public health problem for high income countries, as it occurs in all countries regardless of level of development. Over 80% of asthma deaths occur in low and lower-middle income countries. Asthma is under-diagnosed and under-treated, creating a substantial burden to individuals and families and possibly restricting individuals’ activities for a lifetime.

"Flat USD 2000 OFF"

Buy This Research Study Report @ https://www.coherentmarketinsights.com/promo/buynow/2551

Market Dynamics

The global demand for budesonide inhaler is expected to witness substantial growth over the forecast period, owing to increasing incidences and prevalence of asthma. According to the Global Asthma Report 2018, asthma causes around 1000 deaths every day and affects as many as 339 million people worldwide.

Furthermore, major players in the market are focused on developing new drug combinations for paediatric use. For instance, in January 2017, AstraZeneca announced that the U.S. FDA approved Symbicort (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol for the treatment of asthma in paediatric patients aged 6 to 12 years. Budesonide/formoterol is already approved in the U.S. to treat asthma in patients 12 years and older and for the maintenance treatment of airflow obstruction in Chronic Obstructive Pulmonary Disease (COPD) in adults.

However, product recalls due to failure to meet regulatory guidelines is expected to hinder the market growth. For instance, in 2014, AstraZeneca’s PULMICORT RESPULES (budesonide inhalation suspension) was recalled by the U.S. FDA as budesonide may be above or below the specification range, which can be harmful for the patients.

Key features of the study:

This report provides in-depth analysis of the budesonide inhaler market, market size (US$ Mn), and Compound Annual Growth Rate (CAGR (%)) for the forecast period: 2018 – 2026, considering 2017 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global budesonide inhaler market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies

Request Here PDF Brochure Of This Report @ https://www.coherentmarketinsights.com/insight/request-pdf/2551

Major Key Players Are: Pfizer Inc., Cipla Limited, Lupin Limited, Cosmo Pharmaceuticals, Takeda Pharmaceutical Company Ltd., Manus Aktteva Biopharma LLP, Abbott Laboratories, Lunan Better Pharmaceutical, Novartis International AG (Sandoz), Mylan N.V., Skyepharma, AstraZeneca Plc., Chiesi Farmaceutici S.p.A, Orion Corporation, Santarus Inc., Synmosa Biopharma Corporation, and Shanghai Sine Pharmaceutical Laboratories Co. Ltd.

Table of Content

Global Budesonide Inhaler Market Research Report

Section 1: Global Budesonide Inhaler Industry Overview
Section 2: Global Economic Impact on Budesonide Inhaler Industry
Section 3: Global Market Competition by Industry Producers
Section 4: Global Productions, Revenue (Value), according to Regions
Section 5: Global Supplies (Production), Consumption, Export, Import, geographically
Section 6: Global Productions, Revenue (Value), Price Trend, Product Type
Section 7: Global Market Analysis, on the basis of Application
Section 8: Budesonide Inhaler Market Pricing Analysis
Section 9: Market Chain, Sourcing Strategy, and Downstream Buyers
Section 10: Strategies and key policies by Distributors/Suppliers/Traders
Section 11: Key Marketing Strategy Analysis, by Market Vendors
Section 12: Market Effect Factors Analysis
Section 13: Global Budesonide Inhaler Market Forecast

Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027
Email: sales@coherentmarketinsights.com

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

More Related Reports:

Anti-epileptic Drugs Market - https://www.globenewswire.com/en/news-release/2021/07/29/2271325/0/en/Global-Anti-epileptic-Drugs-Market-to-surpass-US-7-344-9-Million-by-2028-Says-Coherent-Market-Insights-CMI.html

Diabetic Foot Ulcer Treatment Market - https://www.globenewswire.com/en/news-release/2021/07/27/2269469/0/en/Global-Diabetic-Foot-Ulcer-Treatment-Market-to-Surpass-US-12-653-3-Million-by-2028-Owing-to-development-in-non-invasive-treatment-approach-Says-Coherent-Market-Insights-CMI.html

This release was published on openPR.